WHO fact sheet. (2023) https://www.who.int/news-room/fact-sheets/detail/hypertension

Emmanuel B, Boateng, Ama G, Ampofo (2023) A glimpse into the future: modelling global prevalence of hypertension. Publication. Article: February 7, 2023. https://doi.org/10.1186/s12889-023-16662-z

Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Barone Gibbs B, Beaton AZ, Boehme AK, Commodore-Mensah Y, Currie ME, Elkind MSV, Evenson KR, Generoso G, Heard DG, Hiremath S, Johansen MC, Kalani R, Kazi DS, Ko D, Liu J, Magnani JW, Michos ED, Mussolino ME, Navaneethan SD, Parikh NI, Perman SM, Poudel R, Rezk-Hanna M, Roth GA, Shah NS, St-Onge MP, Thacker EL, Tsao CW, Urbut SM, Van Spall HGC, Voeks JH, Wang NY, Wong ND, Wong SS, Yaffe K, Palaniappan LP (2024) American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024;149(8):e347-e913. doi: 10.1161/CIR.0000000000001209. Epub 2024 Jan 24. Erratum in: Circulation. 149(19):e1164. https://doi.org/10.1161/CIR.0000000000001247

Key statistics: Risk factors for cardiovascular disease [Internet]. Heart Foundation. 2023 [cited 2024Oct.13]. https://www.heartfoundation.org.au/your-heart/evidence-and-statistics/key-statistics-risk-factors-for-heart-disease

Ralapanawa, Udaya (2023) RAG-SACA-2.: Epidemiology of Hypertension in South Asia. Journal of Hypertension 41(Suppl 1):e169. https://doi.org/10.1097/01.hjh.0000914376.72916.7e

African Control of Hypertension through Innovative Epidemiology and a Vibrant Ecosystem (ACHIEVE). A holistic approach for hypertension control in Africa Journal of Human Hypertension; https://doi.org/10.1038/s41371-023-00845-7Australia Bureau of Statistics. https://www.heartfoundation.org.au/your-heart/evidence-and-statistics/key-statistics-risk-factors-for-heart-disease

22% of people in the EU have high blood pressure - Products. [Internet]. Eurostat. 2021 [cited 2024Oct.13]. https://ec.europa.eu/eurostat/web/products-eurostat-news/-/edn-20210929-1

Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. (2019) Treatment of resistant and refractory hypertension. Originally Published 28 March 2019. 124(7). https://doi.org/10.1161/CIRCRESAHA.118.312156

Health threats from high blood pressure| American Heart Association [Internet]. 10 Jan 2024 [cited 2024Oct.13]. https://www.heart.org/en/health-topics/high-blood-pressure/health-threats-from-high-blood-pressure

Dechend R. (2016) JS ISH-ESH-3 resistant hypertension - A growing challenge. J Hypertens. 34:e193. https://doi.org/10.1097/01.hjh.0000500422.87914.b9. September.

Article  Google Scholar 

Kahan T. (2016) Guest Editorial challenges in resistant hypertension. Eur Cardiol. 11(1):18–9. https://doi.org/10.15420/ecr.2016:20:1

Article  PubMed  PubMed Central  Google Scholar 

Kumar N, Calhoun DA, Dudenbostel T. (2013) Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control, 139–51, https://doi.org/10.2147/IBPC.S33984

Agabiti-Rosei GBC, Lemoli M, Corvini F. Maria Lorenza Muiesan (2024) The global burden of resistant hypertension and potential treatment options. Published online:19 June 2024. European Cardiology Review. 19:e07. https://doi.org/10.15420/ecr.2023.51

Penn medicine. Renal Denervation. https://www.pennmedicine.org/for-patients-and-visitors/find-a-program-or-service/heart-and-vascular/interventional-cardiology/peripheral-interventions/renal-denervation#:~:text=Renal%20denervation%20reduces%20activity%20in,supplying%20blood%20to%20the%20kidneys

Wagener M, Dolan E, Arnous S, Galvin J, Murphy, et al. (2023) Renal denervation as a complementary treatment option for uncontrolled arterial hypertension: a situation assessment. J Clin Med. 12:5634. https://doi.org/10.3390/jcm12175634.

Article  PubMed  PubMed Central  Google Scholar 

Reyes KRL, Rader F. (2023) Long-term safety and antihypertensive effects of renal denervation: current insights. Integr Blood Press Control. 16:59–70. https://doi.org/10.2147/IBPC.S392410

Article  PubMed  PubMed Central  Google Scholar 

Witkowski A, Januszewicz A, Jadczyk T, Tendera M, Wojakowski W. Catheter-based renal denervation Vol. 10, N° 22 [Internet]. European Society of Cardiology. 2012 [cited 2024Oct.12]. https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-10/Catheter-based-renal-denervation

McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, Christodorescu RM, Daskalopoulou SS, Ferro CJ, Gerdts E, Hanssen H, Harris J, Lauder L, McManus RJ, Molloy GJ, Rahimi K, Regitz-Zagrosek V, Rossi GP, Sandset EC, Scheenaerts B, Staessen JA, Uchmanowicz I, Volterrani M, Touyz RM, ESC Scientific Document Group. (2024) ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 45(38):3912–4018. https://doi.org/10.1093/eurheartj/ehae178

Mohammad AA, Nawar K, Binks O, et al. (2024) Effects of renal denervation on kidney function in patients with chronic kidney disease: a systematic review and meta-analysis. J Hum Hypertens. 38:29–44. https://doi.org/10.1038/s41371-023-00857-3.

Article  PubMed  Google Scholar 

Akumwami S, Morishita A, Iradukunda A, et al. (2023) Possible organ-protective effects of renal denervation: insights from basic studies. Hypertens Res. 46:2661–9. https://doi.org/10.1038/s41440-023-01393-w.

Article  PubMed  Google Scholar 

Sharp TE 3rd, Polhemus DJ, Li Z, Spaletra P, Jenkins JS, Reilly JP, White CJ, Kapusta DR, Lefer DJ, Goodchild TT (2018) Renal denervation prevents heart failure progression via inhibition of the renin-angiotensin system. J Am Coll Cardiol. 72(21):2609–2621. doi: 10.1016/j.jacc.2018.08.2186

Pekarskiy SE, Baev AE, Mordovin VF, Semke GV, Ripp TM, Falkovskaya AU, Lichikaki VA, Sitkova ES, Zubanova IV, Popov SV. (2017) Denervation of the distal renal arterial branches vs. conventional main renal artery treatment: a randomized controlled trial for treatment of resistant hypertension. J Hypertens. 35(2):369–75.

Article  CAS  PubMed  Google Scholar 

Fengler K, Rommel KP, Blazek S, Besler C, Hartung P, von Roeder M, Petzold M, Winkler S, Höllriegel R, Desch S, Thiele H. (2019) A three-arm randomized trial of different renal denervation devices and techniques in patients with resistant hypertension (RADIOSOUND-HTN). Circulation. 139(5):590–600.

Article  PubMed  Google Scholar 

Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, Haskin R, Negoita M, Shimada K. (2015) Symplicity HTN-Japan investigators. SYMPLICITY HTN-Japan–First Randomized Controlled Trial of Catheter-based renal denervation in Asian Patients–. Circ J. 79(6):1222–9.

Article  CAS  PubMed  Google Scholar 

Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, Urata H, Cho JM, Kim CJ, Choi SH, Shinohara K.(2022) Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 45(2):221–31.

Article  PubMed  Google Scholar 

Azizi M, Schmieder RE, Mahfoud F, Weber M, Daemen J, Davies J, Basile J, Kirtane A, Wang Y, Mauri L.(2018) Radiance-HTN Solo: a multicenter, randomized, sham-controlled study of renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications. Journal of Hypertension 36:e238. https://doi.org/10.1097/01.hjh.0000539670.57475.6c

Azizi M, Saxena M, Wang Y, Jenkins JS, Devireddy C, Rader F, Fisher NDL, Schmieder RE, Mahfoud F, Lindsey J, Sanghvi K, Todoran TM, Pacella J, Flack J, Daemen J, Sharp ASP, Lurz P, Bloch MJ, Weber MA, Lobo MD, Basile J, Claude L, Reeve-Stoffer H, McClure CK, Kirtane AJ ( 2023) RADIANCE II Investigators and Collaborators. Endovascular ultrasound renal denervation to treat hypertension: The RADIANCE II randomized clinical trial. JAMA. 2023; 329(8):651–661. doi: 10.1001/jama.2023.0713. Erratum in: JAMA. 329(22):1989. https://doi.org/10.1001/jama.2023.8136

Mahfoud F, Bloch MJ, Azizi M, Wang Y, Schmeider RE, Lobo MD, Sharp ASP, Daemen J, Basile J, Weber MA, Scicli Ap, McClure CK, Kritane AJ (2021) Changes in Blood Pressure after Crossover to Ultrasound Renal Denervation in Patients Initially Treated with Sham in the RADIANCE-HTN SOLO Trial. EuroIntervention, 17(12):1024–e1032, https://doi.org/10.4244/eij-d-21-00295. Accessed 22 Aug. 2022

Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Tsioufis K, Pocock S, Konstantinidis D, Choi JW, East C (2020) Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 395(10234):1444–51

Article  PubMed  Google Scholar 

Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA (2014) A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 370(15):1393–401

Article  CAS  PubMed  Google Scholar 

Weber MA, Kirtane AJ, Weir MR, Radhakrishnan J, Das T, Berk M, Mendelsohn F, Bouchard A, Larrain G, Haase M, Diaz-Cartelle J (2020) The reduce HTN: reinforce: randomized, sham-controlled trial of bipolar radiofrequency renal denervation for the treatment of hypertension. Cardiovasc Interventions. 13(4):461–70

Article  Google Scholar 

Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A, Basile J, Bloch MJ, Daemen J (2021) Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 397(10293):2476–86

Article  CAS  PubMed  Google Scholar 

Peters CD, Mathiassen ON, Vase H, Bech Nørgaard J, Christensen KL, Schroeder AP, Rickers HJ, Opstrup UK, Poulsen PL, Langfeldt S, Andersen G (2017) The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Press. 26(6):366–80.

Article  PubMed  Google Scholar 

Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S (2018) Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 391(10137):2346–55

Article  PubMed  Google Scholar 

Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T ( 2015) Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 385(9981):1957–65.

Article  PubMed  Google Scholar 

Kintscher U, Bakris GL, Kolkhof P (2022) Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 179(13):3220–34

Article  CAS  PubMed  Google Scholar 

Bakris G, Pergola PE, Delgado B, Genov D, Doliashvili T, Vo N, Yang YF, McCabe J, Benn V, Pitt B, BLOCK-CKD Study Group (2021) Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study. Hypertension. 78(1):74–81.

Article  CAS  PubMed  Google Scholar 

Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S (2020) Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study). Hypertension. 75(1):51–8

Article  CAS  PubMed  Google Scholar 

Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, Dreier RF, Sassi-Sayadi M, Haskell LP, Narkiewicz K, Wang JG (2022) Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 400(10367):1927–37

Article  CAS  PubMed  Google Scholar 

Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin PF (2010) Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 56(5):831–8.

Article  CAS  PubMed  Google Scholar 

Bakris GL, Saxena M, Gupta A, Chalhoub F, Lee J, Stiglitz D, Makarova N, Goyal N, Guo W, Zappe D, Desai AS (2024) RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 Randomized Clinical Trial. JAMA. 331(9):740–9.

Article  CAS  PubMed  PubMed Central